302 related articles for article (PubMed ID: 34487971)
21. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
23. Differences in Immunological Landscape between
Luo JW; Guo YH; Wu FY; Li XF; Sun XC; Wang JL; Zhou CC
Dis Markers; 2021; 2021():3776854. PubMed ID: 34484468
[TBL] [Abstract][Full Text] [Related]
24. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
[TBL] [Abstract][Full Text] [Related]
25. Mutation Profile of Resected
Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
[TBL] [Abstract][Full Text] [Related]
26. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
27. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
28. Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy.
Tian P; Zeng H; Ji L; Ding Z; Ren L; Gao W; Fan Z; Li L; Le X; Li P; Zhang M; Xia X; Zhang J; Li Y; Li W
Lung Cancer; 2021 Oct; 160():50-58. PubMed ID: 34403912
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of
Shi L; Xu C; Ma Y; Ou Q; Wu X; Lu S; Shao Y; Guo R; Kong J
ESMO Open; 2020 Nov; 5(6):e000985. PubMed ID: 33214226
[TBL] [Abstract][Full Text] [Related]
30. Deep exploration of immune function in EGFR wild-type and mutated lung adenocarcinomas by gene expression profiling: role of TRAIL-R2 (TNFRSF10B) in patient treatment and outcome.
Chang WC; Yeh YC; Ho HL; Chou TY
Hum Pathol; 2022 Aug; 126():9-18. PubMed ID: 35550831
[TBL] [Abstract][Full Text] [Related]
31. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
Costa DB; Jorge SE; Moran JP; Freed JA; Zerillo JA; Huberman MS; Kobayashi SS
J Thorac Oncol; 2016 Jun; 11(6):918-23. PubMed ID: 26964772
[TBL] [Abstract][Full Text] [Related]
32. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
33. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
[TBL] [Abstract][Full Text] [Related]
34. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
[TBL] [Abstract][Full Text] [Related]
35. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
36.
Sentana-Lledo D; Academia E; Viray H; Rangachari D; Kobayashi SS; VanderLaan PA; Costa DB
Transl Lung Cancer Res; 2023 Jul; 12(7):1590-1610. PubMed ID: 37577308
[TBL] [Abstract][Full Text] [Related]
37. Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.
Wilding B; Scharn D; Böse D; Baum A; Santoro V; Chetta P; Schnitzer R; Botesteanu DA; Reiser C; Kornigg S; Knesl P; Hörmann A; Köferle A; Corcokovic M; Lieb S; Scholz G; Bruchhaus J; Spina M; Balla J; Peric-Simov B; Zimmer J; Mitzner S; Fett TN; Beran A; Lamarre L; Gerstberger T; Gerlach D; Bauer M; Bergner A; Schlattl A; Bader G; Treu M; Engelhardt H; Zahn S; Fuchs JE; Zuber J; Ettmayer P; Pearson M; Petronczki M; Kraut N; McConnell DB; Solca F; Neumüller RA
Nat Cancer; 2022 Jul; 3(7):821-836. PubMed ID: 35883003
[TBL] [Abstract][Full Text] [Related]
38. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
39. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
Le X; Negrao MV; Reuben A; Federico L; Diao L; McGrail D; Nilsson M; Robichaux J; Munoz IG; Patel S; Elamin Y; Fan YH; Lee WC; Parra E; Solis Soto LM; Chen R; Li J; Karpinets T; Khairullah R; Kadara H; Behrens C; Sepesi B; Wang R; Zhu M; Wang L; Vaporciyan A; Roth J; Swisher S; Haymaker C; Zhang J; Wang J; Wong KK; Byers LA; Bernatchez C; Zhang J; Wistuba II; Gibbons DL; Akbay EA; Heymach JV
J Thorac Oncol; 2021 Apr; 16(4):583-600. PubMed ID: 33388477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
